Check out our deep dive in MSI-H gastric cancer, now out in @CD_AACR . Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer

RT @ArndtVogel: Givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in mGEC.🔎Phase I/II.👉….

RT @SunnieSKim: FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the….

RT @FASinicropeMD: Enjoying interacting with other speakers and discussants during today’s plenary. Exciting new data was presented. https….

RT @ElizSMcKenna: Attending the #AACR25 session on Innovative Paradigms in Immunotherapy Combos in Gastric Cancer? Read speaker @KlempnerSa….

Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial. @JeeyunM @AnMinae @arnavmehta3 @CCR_AACR.

Proof of principle in KRAS G12C CRC, analogous to EGFR rechallenge in RAS WT Colon cancer. @MGHCancerCenter @JCOPO_ASCO . Anti-KRAS G12C + Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer.

Cool paper from @ShadiEsfahani and team in @ScienceTM @MGHCancerCenter . Development of a fibrin-targeted theranostic for gastric cancer | Science Translational Medicine

RT @SCIDirector: SCI members @HowardYChang, @mischellab, and others found that blocking #CHK1 activity leads to death of #ecDNA containing….

Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy | Journal of Clinical Oncology

Adding to the ever growing approaches in GEA. @JCO_ASCO @ASCO. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish |

Great to have another option for patients. @KoheiShitara @mdmanishshah @ILSONDavid @FlorianLordick @sara_lonardi1 and many others. FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma via @onclive.

RT @KoheiShitara: Pleased to share final survival results of two phase 3 of zolbetuximab @NEJM  which reinforce zolbetuxumab plus chemo as….

RT @sundar__raghav: Building one of the largest datasets of gastric cancer peritoneal metastases in the world, we unravel new biology of or….

Congratulations to Harsh Singh and @DanaFarber team for getting this data out. CAPOX + Trastuzumab + Bevacizumab in frontline HER2+ gastroesophageal. @NatureComms @JamesClearyMD @DrRonanKelly and others . -- full paper.

RT @ASCOPres: I'd like to call attn. to an outstanding professional development opportunity, the @ASCO Leadership Development Program! I se….

RT @KEN_K_: I am pleased to inform you that the primary result of JCOG1109 was published in the Lancet today. The neoadjuvant triplet chemo….

RT @ElizSMcKenna: The June issue of @CD_AACR is online! On the cover: Efficacy and Safety of Adagrasib + Cetuximab in Patients w/#KRAS G12C….

RT @MyriamChalabi: #ASCO24 plenary: ESOPEC 👏👏.👉🏼neoadj CROSS vs peri-op FLOT in pts with EAC.👉🏼221 in FLOT vs 217 CROSS arm.👉🏼 Median OS: 6….

RT @JCOPO_ASCO: ‼️ #ASCO24 simultaneous publication by @KlempnerSam et al: . PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Co….

RT @CD_AACR: New from the May issue—.Sequential chemoimmunotherapy in #gastriccancer, by @AnMinae, @arnavmehta3, Byung Hoon Min, You Jeong….